Do we start with another medication for weight loss
10.7759/cureus.37783 253
Risk of developing PTSD is influenced by adverse childhood experiences, younger age and socioeconomic disadvantage (Xue et al., 2015) with prevalence rates twice as high in females than in males (Perrin et al., 2014)
The SUMMIT trial for Eli Lillys GLP-1/GIP drug, tirzepatide, found it reduced mortality risks in HFpEF patients with obesity
This finding has significant implications for anyone who has received steroid injections for hip problems and may be experiencing delayed recovery as a result
(A, B, C) Cells were pretreated with 1, 10, 100 and 1000 nM GLP-1 for 12 h, HDAC6 and ac--tubulin were detected by Western blot